NaviFUS Corp.
NaviFUS Corp., a medical device company, develops and sells focused ultrasound (FUS) solutions for the unmet needs in neuromedicine in Taiwan. The company develops NaviFUS, a neuronavigator-guided transcranial FUS system that delivers focal energy into deep tissues in the brain, as well as is used in various clinical applications, such as drug delivery, neuromodulation, immuno-stimulation, and ot… Read more
NaviFUS Corp. (6872) - Net Assets
Latest net assets as of September 2025: NT$607.14 Million TWD
Based on the latest financial reports, NaviFUS Corp. (6872) has net assets worth NT$607.14 Million TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$659.59 Million) and total liabilities (NT$52.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$607.14 Million |
| % of Total Assets | 92.05% |
| Annual Growth Rate | -4.41% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 11.66 |
NaviFUS Corp. - Net Assets Trend (2021–2024)
This chart illustrates how NaviFUS Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NaviFUS Corp. (2021–2024)
The table below shows the annual net assets of NaviFUS Corp. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$492.65 Million | +12.70% |
| 2023-12-31 | NT$437.13 Million | -13.07% |
| 2022-12-31 | NT$502.88 Million | -10.84% |
| 2021-12-31 | NT$564.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NaviFUS Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22444700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$1.02 Billion | 212.11% |
| Total Equity | NT$481.50 Million | 100.00% |
NaviFUS Corp. Competitors by Market Cap
The table below lists competitors of NaviFUS Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shen's Art Printing Co., Ltd.
TWO:8921
|
$5.07K |
|
Avemio AG
XETRA:AV2
|
$5.08K |
|
African Dawn Capital Ltd
JSE:ADW
|
$5.08K |
|
Bank BBVA Peru
LIM:BBVAC1
|
$5.08K |
|
Elite Capital Modaraba 1st
KAR:ELCM
|
$5.06K |
|
CICC Fund Management Co Ltd - CICC Xiamen Affordable Rental Housing Infrastructure - Fund
SHG:508058
|
$5.06K |
|
Nextgen Food Robotics Corp
PINK:NGRBF
|
$5.05K |
|
Tom Tailor Holding SE
HM:TTI
|
$5.05K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NaviFUS Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 422,996,000 to 481,504,000, a change of 58,508,000 (13.8%).
- Net loss of 95,125,000 reduced equity.
- New share issuances of 150,090,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-95.12 Million | -19.76% |
| Share Issuances | NT$150.09 Million | +31.17% |
| Other Changes | NT$3.54 Million | +0.74% |
| Total Change | NT$- | 13.83% |
Book Value vs Market Value Analysis
This analysis compares NaviFUS Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.21x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.78x to 2.21x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$9.59 | NT$17.05 | x |
| 2022-12-31 | NT$8.51 | NT$17.05 | x |
| 2023-12-31 | NT$7.42 | NT$17.05 | x |
| 2024-12-31 | NT$7.72 | NT$17.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NaviFUS Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -345.53%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.14x
- Recent ROE (-19.76%) is below the historical average (-15.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -15.15% | 0.00% | 0.00x | 1.08x | NT$-137.44 Million |
| 2022 | -13.11% | -325.68% | 0.04x | 1.08x | NT$-112.09 Million |
| 2023 | -15.54% | -292.38% | 0.05x | 1.16x | NT$-108.03 Million |
| 2024 | -19.76% | -345.53% | 0.05x | 1.14x | NT$-143.28 Million |
Industry Comparison
This section compares NaviFUS Corp.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,274,214,400
- Average return on equity (ROE) among peers: 6.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NaviFUS Corp. (6872) | NT$607.14 Million | -15.15% | 0.09x | $5.07K |
| Health & Life Co., Ltd. (1781) | $372.58 Million | -4.71% | 1.15x | $12.97 Million |
| Hi-Clearance (1788) | $3.00 Billion | 11.98% | 0.65x | $104.25 Million |
| Radiant Innovation (3373) | $865.89 Million | -3.30% | 0.08x | $18.65 Million |
| Wellell Inc (4106) | $1.31 Billion | 13.81% | 0.24x | $37.12 Million |
| Rossmax International Ltd (4121) | $1.33 Billion | 1.93% | 1.30x | $38.32 Million |
| United Orthopedic (4129) | $1.77 Billion | 7.55% | 0.46x | $300.33 Million |
| Dynamic Medical Technologies (4138) | $1.76 Billion | 11.67% | 0.71x | $39.41 Million |
| Ok Biotech Co Ltd (4155) | $1.30 Billion | 9.66% | 0.71x | $44.61 Million |
| Bioptik Technology (4161) | $717.83 Million | 6.76% | 1.11x | $30.42 Million |
| EPS Bio Technology Corp. (4183) | $309.15 Million | 10.25% | 0.77x | $4.27 Million |